IIM
MRSN

INTECH Investment Management’s Mersana Therapeutics MRSN Stock Holding History

INTECH Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,614
Closed -$31.1K – 2593
2025
Q1 		$31.1K Buy
3,614
+1,573
+77% +$24.3K ﹤0.01% 2479
2024
Q4 		$73K Buy
2,041
+947
+87% +$49K ﹤0.01% 2274
2024
Q3 		$51.7K Buy
+1,094
New +$48.3K ﹤0.01% 1980

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

INTECH Investment Management's MRSN Position: Q2 2025 in Review

INTECH Investment Management sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 3,614 shares — an estimated $31.1K sold.

INTECH Investment Management first reported a position in MRSN in Q3 2024 and held it in 3 quarters. The position peaked at $73K in Q4 2024. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • INTECH Investment Management reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 3,614 Mersana Therapeutics shares in Q2 2025, an estimated $31.1K.
  • INTECH Investment Management first reported a position in Mersana Therapeutics in Q3 2024 and held it in 3 quarters.
  • INTECH Investment Management's Mersana Therapeutics position peaked at $73K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.